STAMPEDE试验中随机接受多西他赛或阿比特龙治疗的前列腺癌男性的生活质量
STAMPEDE试验中515例患者随机接受多西他赛+标准治疗或醋酸阿比特龙+泼尼松/泼尼松龙(AAP)+标准治疗,评估2年内全球生活质量(QOL)差异。AAP+标准治疗组2年平均全球QOL评分高3.9分(95%CI +0.5至+7.2;P=0.022),第一年内高5.7分(95%CI +3.0至+8.5;P<0.001),但未达到预设的临床意义阈值(>4.0分)。
要点
- AAP+标准治疗组2年平均全球QOL评分较多西他赛+标准治疗组高3.9分(95%CI +0.5至+7.2;P=0.022)。
- AAP+标准治疗组第一年内全球QOL评分较高,第12周高7.0分(95%CI +3.0至+11.0;P=0.001),第24周高8.3分(95%CI +4.0至+12.6;P<0.001)。
- 2年差异未达到预设的临床意义阈值(>4.0分),但第一年内差异具有临床意义。
核心结论
- 在接受标准治疗的基础上,随机分配至AAP+标准治疗的患者报告的生活质量优于多西他赛+标准治疗患者,2年差异接近但未达到预设的临床意义阈值。
- AAP+标准治疗组在随机分配后第一年内报告了具有临床意义的更高全球QOL评分。
研究设计与样本
- STAMPEDE试验中同期入组并可随机分配至多西他赛+标准治疗或AAP+标准治疗的患者。
- 纳入至少完成一份QLQ-C30+PR25问卷的患者共515例(多西他赛+标准治疗组173例,AAP+标准治疗组342例),采用混合模型评估QOL。
- 主要结局为随机分配后2年内全球QOL(QLQ-C30 Q29&30)差异,预设临床意义差异标准为>4.0分。
主要发现
- 两组基线特征、缺失数据比例和平均基线全球QOL评分相似(多西他赛+标准治疗组77.8,AAP+标准治疗组78.0)。
- 随机分配后2年内,AAP+标准治疗组平均模型化全球QOL评分较多西他赛+标准治疗组高3.9分(95%CI +0.5至+7.2;P=0.022)。
- 第一年内AAP+标准治疗组全球QOL较高(+5.7分,95%CI +3.0至+8.5;P<0.001),第12周高7.0分(95%CI +3.0至+11.0;P=0.001),第24周高8.3分(95%CI +4.0至+12.6;P<0.001)。
关键数值与推荐
- 主要结局预设临床意义差异标准为>4.0分。
- 2年全球QOL差异为+3.9分(95%CI +0.5至+7.2;P=0.022),未达到预设阈值。
- 第一年全球QOL差异为+5.7分(95%CI +3.0至+8.5;P<0.001),超过预设阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices. METHODS: A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC. A mixed-model assessed QOL in those who had completed at least one QLQ-C30 + PR25 questionnaire. The primary outcome measure was difference in global-QOL (QLQ-C30 Q29&30) between patients allocated to docetaxel + SOC or AAP + SOC over the 2 years after random assignment, with a predefined criterion for clinically meaningful difference of > 4.0 points. Secondary outcome measures included longitudinal comparison of functional domains, pain, and fatigue, plus global-QOL at defined timepoints. RESULTS: Five hundred fifteen patients (173 docetaxel + SOC and 342 AAP + SOC) were included. Baseline characteristics, proportion of missing data, and mean baseline global-QOL scores (docetaxel + SOC 77.8 and AAP + SOC 78.0) were similar. Over the 2 years following random assignment, the mean modeled global-QOL score was +3.9 points (95% CI, +0.5 to +7.2; P = .022) higher in patients allocated to AAP + SOC. Global-QOL was higher for patients allocated to AAP + SOC over the first year (+5.7 points, 95% CI, +3.0 to +8.5; P < .001), particularly at 12 (+7.0 points, 95% CI, +3.0 to +11.0; P = .001) and 24 weeks (+8.3 points, 95% CI, +4.0 to +12.6; P < .001). CONCLUSION: Patient-reported QOL was superior for patients allocated to receive AAP + SOC, compared with docetaxel + SOC over a 2-year period, narrowly missing the predefined value for clinical significance. Patients receiving AAP + SOC reported clinically meaningful higher global-QOL scores throughout the first year following random assignment.
引用
- Rush HL, Murphy L, Morgans AK, et al. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. J Clin Oncol. 2021. PMID: 34757812. doi:10.1200/JCO.21.00728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。